Size : | Price | Quantity | |
---|---|---|---|
25 mg | $50.00 | ||
100 mg | $165.00 |
Gimeracil (103766-25-2) is a dihydropyrimidine dehydrogenase (DPD) inhibitor. DPD is involved in the degradation of pyrimidine-based chemotherapeutic drugs such as 5-fluorouracil (5-FU). Gimeracil is used along with 5-FU or Tegafur to prolong circulating concentrations of the drugs.1,2 Gimeracil has also been shown to act as a radiosensitizer via inhibition of homologous recombination in the repair of DNA double strand breaks.3
References/Citations:
1) Diasio (1999) Clinical implications of dihydropyrimidine dehydrogenase inhibition; Oncology(Williston Park), 13 17
2) Kobayakawa and Kojima (2011), Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies; Onco. Targets Ther., 4 193
3) Sakata et al. (2011), Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination; Cancer Sci., 102 1712
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Gimeracil (103766-25-2) is a dihydropyrimidine dehydrogenase (DPD) inhibitor. DPD is involved in the degradation of pyrimidine-based chemotherapeutic drugs such as 5-fluorouracil (5-FU). Gimeracil is used along with 5-FU or Tegafur to prolong circulating concentrations of the drugs.1,2 Gimeracil has also been shown to act as a radiosensitizer via inhibition of homologous recombination in the repair of DNA double strand breaks.3
References/Citations:
1) Diasio (1999) Clinical implications of dihydropyrimidine dehydrogenase inhibition; Oncology(Williston Park), 13 17
2) Kobayakawa and Kojima (2011), Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies; Onco. Targets Ther., 4 193
3) Sakata et al. (2011), Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination; Cancer Sci., 102 1712
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.